Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized penehyclidine hydrochloride for lung protection in obese OSA patients after laparoscopic sleeve gastrectomy
ChiCTR2500112331Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine in obesity, obstructive sleep apnea hypopnea syndrome (OSAHS), cardiometabolic risk (CMR) and 3 more (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Area under the driving pressure curve (ArAUC). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
obesityobstructive sleep apnea hypopnea syndrome (OSAHS)cardiometabolic risk (CMR)postoperative respiratory complications (PRC)atelectasis
Beyond the preview
Go deeper on ChiCTR2500112331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112331.